Acutaas Chemicals Limited
NSE: ACUTAASMarket Closed • NSE
Day range
52 week range
Acutaas Chemicals Limited closed at INR3206.00 (+2.35%) on volume 1.35x its 20-day average, trading 14.28% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -44% QoQ
2026-09-17
DIVIDEND Announced
Dividend - Rs 2.50 Per Share
2025-09-18
DIVIDEND Announced
Dividend - Rs 1.50 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 31.6%
Risks
Elevated Leverage Burden: Debt-to-Equity stands at 2.08x
Stretched Valuation: Trading at a high P/E multiple of 68.2x
Bull case
Market Leadership: Established operational scale in Specialty Chemicals.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 17 Sept 2026 | Dividend | ₹2.50 / share | — | 17 Sept 2026 |
| 18 Sept 2025 | Dividend | ₹1.50 / share | — | 18 Sept 2025 |
| 25 Apr 2025 | Dividend | ₹10.00 / share | — | 25 Apr 2025 |
| — | Annual General Meeting | Annual General Meeting | — | 13 Sept 2024 |
| 13 Sept 2024 | Dividend | ₹3.00 / share | — | 13 Sept 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 18 Sept 2023 |
| 18 Sept 2023 | Dividend | ₹3.00 / share | — | 18 Sept 2023 |
| — | Dividend | ₹3.00 / share | — | 29 Jul 2022 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 UltraTech Cement LimitedULTRACEMCO Open analysis | ₹3.21L | 37.59 | 2.21% | ₹25,799.47 | ₹2,982.76 | +11.86% | +20.17% |
 JSW Steel LimitedJSWSTEEL Open analysis | ₹2.97L | 12.05 | 0.59% | ₹47,364.00 | ₹4,651.00 | +11.55% | +112.96% |
 Hindustan Zinc LimitedHINDZINC Open analysis | ₹2.28L | 13.37 | 2.07% | ₹13,687.00 | ₹5,425.00 | +77.22% | +146.14% |
 Asian Paints LimitedASIANPAINT Open analysis | ₹2.24L | 46.94 | 1.17% | ₹10,541.94 | ₹1,539.25 | +17.94% | +39.96% |
 Tata Steel LimitedTATASTEEL Open analysis | ₹2.19L | 19.83 | 2.27% | ₹60,794.00 | ₹2,385.00 | +14.32% | +18.83% |
 Hindalco Industries LimitedHINDALCO Open analysis | ₹2.02L | 12.32 | 0.56% | ₹84,825.00 | ₹7,013.00 | +32.06% | +75.15% |
 Grasim Industries LimitedGRASIM Open analysis | ₹1.98L | 34.82 | 0.35% | ₹11,794.71 | ₹246.65 | -70.60% | -82.61% |
 Solar Industries India LimitedSOLARINDS Open analysis | ₹1.81L | 90.93 | 0.06% | ₹3,668.00 | ₹666.00 | +70.29% | +88.67% |
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.[1]
IndiaBasic Materials
Is Acutaas Chemicals Limited Shariah compliant?
Acutaas Chemicals Limited is currently screened as Non-Compliant (Financial Ratios) under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (208.1%) exceeds AAOIFI threshold (≤ 33%).
What is Acutaas Chemicals Limited's current valuation relative to peers?
Acutaas Chemicals Limited trades at a P/E of 68.2x compared to the sector median of 21.9x, and a Price-to-Book of 15.9x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 2.08x. Interest coverage is comfortable.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 6% while net profit growth averaged 17.6%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.